Laura Fernández Landó

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet · 2021 · 1K citations

Medicine, Pharmacology, Pharmacotherapy +16

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet · 2021 · 610 citations

Medicine, Pharmacology, Pharmacotherapy +16

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó et al. · The Lancet Diabetes & Endocrinology · 2022 · 479 citations

Medicine, Endocrinology, Internal Medicine +17

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes

Julio Rosenstock, Juan P. Frías, Helena W. Rodbard et al. · JAMA · 2023 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17